![Richard Adams B.Med.Sci, BM BS, MRCP, FRCR, MD](https://profiles-cardiff.imgix.net/attachments/219?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Richard Adams
B.Med.Sci, BM BS, MRCP, FRCR, MD
Clinical Reader
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwyg
Richard Adams is Professor and Honorary Consultant Clinical Oncologist at Cardiff University and Velindre Cancer Centre. He is Director of Cancer Trials for the Centre for Trials Research and Director of the Wales Cancer Bank. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the National Cancer Research Institute anorectal cancer and CTRad WS2 (UK radiotherapy research) subgroups. He is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD.
Richard chairs the biomarker development group for the UK phase III FOCUS4 trial in metastatic colorectal cancer and is Chief investigator for the FOCUS4 D and F trials. He leads on the radiotherapy quality assurance programme for the UK ARISTOTLE and SAILOR trials. He has a role within Wales to engage researchers in translational research and leads work package 3 of the Wales Cancer Research Centre. He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Sierra Leone Cancer Care link..
Cyhoeddiad
2024
- Adams, R., Drinkwater, K., Gilbert, D. C., Hawkins, M. A., Montefiore, D. S., Thorpe, N. and Muirhead, R. 2024. The impact of national radiotherapy guidelines: the UK anal cancer story. Clinical Oncology 36, pp. 593-595. (10.1016/j.clon.2024.06.048)
- Ajakaiye, A. et al. 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting, Dublin, Ireland, 16-18 October 2024, Vol. 34. BMJ Publishing Group pp. A350-A351., (10.1136/ijgc-2024-IGCS.611)
- Cohen, R. et al. 2024. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. European Journal of Cancer 207, article number: 114160. (10.1016/j.ejca.2024.114160)
- Murphy, A. D. et al. 2024. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. International Journal of Gynecological Cancer 34, pp. 1034-1040. (10.1136/ijgc-2024-005455)
- Karapetis, C. S. et al. 2024. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. British Journal of Cancer 130, pp. 1269–1278. (10.1038/s41416-024-02604-y)
- Cohen, R. et al. 2024. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. European Journal of Cancer 199, article number: 113537. (10.1016/j.ejca.2024.113537)
- Coyle, V. et al. 2024. Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial. Clinical Microbiology and Infection 30(1), pp. 92-99. (10.1016/j.cmi.2023.07.021)
- Elwood, P. et al. 2024. Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against. British Journal of Cancer 130, pp. 3-8. (10.1038/s41416-023-02506-5)
2023
- Retzer, A. et al. 2023. Development of a core outcome set for use in adult primary glioma phase III interventional trials: A mixed methods study. Neuro-Oncology Advances 5(1), article number: vdad096. (10.1093/noajnl/vdad096)
- Jones, S. E. F. et al. 2023. Launching the PICCOS trial: PIPAC in cancers of the colon, ovary and stomach. Presented at: European Society of Gynaecological Society Congress, Istanbul, Turkey, 28 September - 01 October 2023. BMJ Publishing Group, (10.1136/ijgc-2023-ESGO.690)
- Richman, S. D. et al. 2023. FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology 76(8), pp. 548-554. (10.1136/jclinpath-2022-208233)
- Ou, F. et al. 2023. Evaluation of intratumoral response heterogeneity in metastatic colorectal cancer and Its impact on patient overall survival: findings from 10,551 patients in the ARCAD database. Cancers 15(16), article number: 4117. (10.3390/cancers15164117)
- Mukherjee, S. et al. 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61, article number: 102059. (10.1016/j.eclinm.2023.102059)
- Spary, L. K. et al. 2023. Clinical analysis of the colorectal cohort within the Wales cancer biobank: a study of outcomes and genetic screening. Journal of Cancer Therapy 14(7), pp. 317-344. (10.4236/jct.2023.147027)
- Margalit, O. et al. 2023. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.. European Journal of Cancer 178, pp. 162-170. (10.1016/j.ejca.2022.10.022)
2022
- Brown, L. C. et al. 2022. Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. Efficacy and Mechanism Evaluation 9, article number: 9. (10.3310/HTNB6908)
- Franko, J. et al. 2022. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. European Journal of Cancer 174, pp. 142-152. (10.1016/j.ejca.2022.07.021)
- Retzer, A. et al. 2022. Core outcomes in brain tumour trials – the COBra study review of glioma trial registration data. Presented at: BNOS 2022, Liverpool, 22-24 June 2022, Vol. 24. Oxford University Press, (10.1093/neuonc/noac200.019)
- Retzer, A. et al. 2022. Development of a core outcome set and identification of patient-reportable outcomes for primary brain tumour trials: protocol for the COBra study. BMJ Open 12, article number: 57712. (10.1136/bmjopen-2021-057712)
- Henderson, R. H. et al. 2022. Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. Journal of Cancer Policy 33, article number: 100342. (10.1016/j.jcpo.2022.100342)
- Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
- Brown, S. R. et al. 2022. A road map for designing phase I clinical trials of radiotherapy-novel agent combinations. Clinical Cancer Research 28(17), pp. 3639-3651. (10.1158/1078-0432.CCR-21-4087)
- Margalit, O. et al. 2022. P-106 Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. Annals of Oncology 33(S4), pp. S287-S287. (10.1016/j.annonc.2022.04.196)
- Speirs, V., Cox, A., Chelala, C., James, J. A., Adams, R. A. and Jones, J. L. 2022. A biobank perspective on use of tissue samples donated by trial participants. The Lancet Oncology 23(5), article number: e205. (10.1016/S1470-2045(22)00186-3)
- McCleary, N. J. et al. 2022. Metastatic colorectal cancer outcomes by age among ARCAD first- and second-line Clinical trials. JNCI Cancer Spectrum 6(2), article number: pkac014. (10.1093/jncics/pkac014)
- Adams, R., Wilson, R., Brown, L. and Maughan, T. 2022. Reply to A. Kurreck et al and M.S. Copur et al. Journal of Clinical Oncology 40(11), pp. 1263-1264. (10.1200/JCO.21.02806)
- Brown, L. C. et al. 2022. Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials 19(2), pp. 146-157. (10.1177/17407745211069879)
- Papamichael, D. et al. 2022. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. European Journal of Cancer 163, pp. 1-15. (10.1016/j.ejca.2021.12.007)
- Goldberg, R. M. et al. 2022. Clinical trial endpoints in metastatic cancer: using individual participant data to inform future trials methodology. Journal of the National Cancer Institute 114(6), pp. 819-828. (10.1093/jnci/djab218)
- Baddeley, E. et al. 2022. Evaluation of patient and public involvement in the development of a patient reported outcome set in brain tumour trials (COBra Study). Presented at: National PROMs Annual Research Conference, National, 14-15 June 2022.
2021
- Yin, J. et al. 2021. Prognostic and predictive impact of primary tumor sidedness for previously untreated advanced colorectal cancer. Journal of the National Cancer Institute 113(12), pp. 1705-1713., article number: djab112. (10.1093/jnci/djab112)
- Clifford, R. E., Harji, D., Poynter, L., Jackson, R., Adams, R., Fearnhead, N. S. and Vimalachandran, D. 2021. Rectal cancer management during the COVID-19 pandemic (ReCaP): multicentre prospective observational study. British Journal of Surgery 108(11), pp. 1270-1273., article number: znab129. (10.1093/bjs/znab129)
- Adams, R. A. et al. 2021. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology 39(33), pp. 3693-3704. (10.1200/JCO.21.01436)
- Seligmann, J. F. et al. 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology 39(33), pp. 3705-3715. (10.1200/JCO.21.01435)
- Cohen, R. et al. 2021. BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. JNCI: Journal of the National Cancer Institute 113(10), pp. 1386–1395-1395. (10.1093/jnci/djab042)
- ten Hoorn, S. et al. 2021. Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer 125, pp. 1080-1088. (10.1038/s41416-021-01477-9)
- Adams, R. et al. 2021. Treatment breaks in first line treatment of advanced colorectal cancer: an individual patient data meta-analysis. Cancer Treatment Reviews 99, article number: 102226. (10.1016/j.ctrv.2021.102226)
- Henderson, R. H. et al. 2021. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. The Lancet Gastroenterology & Hepatology 6(9), pp. 709-722. (10.1016/S2468-1253(21)00147-3)
- Hanna, C. R. et al. 2021. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology 16(1), article number: 163. (10.1186/s13014-021-01888-1)
- Hanna, C. R., O'Cathail, S. M., Graham, J., Adams, R. and Roxburgh, C. S. 2021. Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology 4(2), pp. 86-104. (10.36401/JIPO-20-31)
- RECOVERY Collaborative Group, ., Adams, R. and Forton, J. 2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet 397(10289), pp. 2049-2059. (10.1016/s0140-6736(21)00897-7)
- Abani, O. et al. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397(10285), pp. 1637-1645. (10.1016/S0140-6736(21)00676-0)
- Hanna, C. et al. 2021. Intensity-modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology 33(4), pp. 214-223. (10.1016/j.clon.2020.12.011)
- Bach, S. P. et al. 2021. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterology and Hepatology 6(2), pp. 92-105. (10.1016/S2468-1253(20)30333-2)
- Horby, P. et al. 2021. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 384(8), pp. 693-704. (10.1056/NEJMoa2021436)
- Abaleke, E. et al. 2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397(10274), pp. 605-612. (10.1016/S0140-6736(21)00149-5)
- Yin, J. et al. 2021. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology 13, pp. 1-11. (10.1177/17588359211020547)
- Jayson, G. et al. 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference, 2021.
2020
- Horby, P. et al. 2020. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine 383(21), pp. 2030-2040. (10.1056/NEJMoa2022926)
- Glynne-Jones, R., Meadows, H., Lopes, A., Muirhead, R., Sebag-Montefiore, D. and Adams, R. 2020. Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. Annals of Oncology 31(11), pp. 1587-1588. (10.1016/j.annonc.2020.08.2097)
- Glynne-Jones, R., Meadows, H. M., Lopes, A., Muirhead, R., Sebag-Montefiore, D. and Adams, R. 2020. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Annals of Oncology 31(10), pp. 1376-1385. (10.1016/j.annonc.2020.06.012)
- Germetaki, T. et al. 2020. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncology 16(28), pp. 2177-2189. (10.2217/fon-2020-0523)
- Barber, P. R. et al. 2020. HER2-HER3 heterodimer quantification by FRET-FILM and patient subclass analysis of the COIN colorectal trial. JNCI: Journal of the National Cancer Institute 112(9), pp. 944-954. (10.1093/jnci/djz231)
- Karapetis, C. S. et al. 2020. 434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database. Annals of Oncology 31(S4), article number: S426. (10.1016/j.annonc.2020.08.545)
- Papamichael, D. et al. 2020. 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database. Annals of Oncology 31, article number: S425. (10.1016/j.annonc.2020.08.543)
- Rao, S. et al. 2020. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil cersus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology 38(22), pp. 2510-2518. (10.1200/JCO.19.03266)
- O'Cathail, S. M. et al. 2020. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology 15, article number: 151. (10.1186/s13014-020-01593-5)
- Forde, C. et al. 2020. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials 21, article number: 431. (10.1186/s13063-020-04241-1)
- Gilbert, A. et al. 2020. UK national cohort of anal cancer treated with intensity-modulated radiotherapy: one-year oncological and patient-reported outcomes. European Journal of Cancer 128, pp. 7-16. (10.1016/j.ejca.2019.12.022)
- Chalmers, A. et al. 2020. CTRad 10 years on: from 10-point plan to top 10 achievements. Clinical Oncology 32(1), pp. 9-12. (10.1016/j.clon.2019.09.043)
2019
- Joharatnam-Hogan, N. et al. 2019. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology 4(11), pp. 854-862. (10.1016/S2468-1253(19)30289-4)
- Gilbert, A. et al. 2019. 535P - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5). Annals of Oncology 30(S5), pp. v203-v204. (10.1093/annonc/mdz246.013)
- Vallance, A. et al. 2019. Making an IMPACT: A priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer. EJSO - European Journal of Surgical Oncology 45(9), pp. 1467-1574. (10.1016/j.ejso.2019.04.005)
- Renehan, A. et al. 2019. Early stage anal margin cancer: towards evidence‐based management. Colorectal Disease 21(4), pp. 387-391. (10.1111/codi.14571)
2018
- Fish, R. et al. 2018. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterology and Hepatology 3(12), pp. 865-873. (10.1016/S2468-1253(18)30264-4)
- West, H. et al. 2018. Role for nucleotide excision repair gene variants in oxaliplatin-induced peripheral neuropathy. JCO Precision Oncology 2, pp. 1-18. (10.1200/PO.18.00090)
- Salem, M. E. et al. 2018. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. European Journal of Cancer 103, pp. 205-213. (10.1016/j.ejca.2018.08.020)
- Cross, W. et al. 2018. The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution 2(10), pp. 1661-1672. (10.1038/s41559-018-0642-z)
- Elwood, P. et al. 2018. Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. PLoS ONE 13(9), pp. e0203957. (10.1371/journal.pone.0203957)
- Madi, A. et al. 2018. Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII22., (10.1093/annonc/mdy269.072)
- Rao, S. et al. 2018. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII715-VIII716., (10.1093/annonc/mdy424.022)
- Madi, A. et al. 2018. Pharmacogenetic analyses of 2,183 patients with advanced colorectal cancer; Potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.. European Journal of Cancer 102, pp. 31-39. (10.1016/j.ejca.2018.07.009)
- Goey, K. K. et al. 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer 100, pp. 35-45. (10.1016/j.ejca.2018.05.010)
- Gollins, S. et al. 2018. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer (10.1038/s41416-018-0209-4)
- Jones, C. M. et al. 2018. Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort. International Journal of Radiation Oncology - Biology - Physics 101(5), pp. 1202-1211. (10.1016/j.ijrobp.2018.04.033)
- Sjoquist, K. M. et al. 2018. Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project. JNCI: Journal of the National Cancer Institute 110(6), pp. 638-648. (10.1093/jnci/djx253)
- Rose, G. et al. 2018. The cardiopulmonary exercise test grey zone; optimising fitness stratification by application of critical difference. British Journal of Anaesthesia 120(6), pp. 1187-1194. (10.1016/j.bja.2018.02.062)
- Bhoday, J., Glimelius, B., Tait, D., Glynne-Jones, R., Adams, R. and Brown, G. 2018. Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. Presented at: Future Horizons International Experts Meeting in Colorectal Cancer 2015, London, England, 25 June 2015 Presented at Wale, A. and Brown, G. eds., Vol. 20. Vol. S`. Wiley pp. 97-99., (10.1111/codi.14088)
- Alderdice, M. et al. 2018. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. The Journal of Pathology 245(1), pp. 19-28. (10.1002/path.5051)
- Adams, R. et al. 2018. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2?3 randomised trial. Lancet Gastroenterology and Hepatology 3(3), pp. 162-171. (10.1016/S2468-1253(17)30394-1)
- Lawler, M. et al. 2018. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut 67(1), pp. 179-193. (10.1136/gutjnl-2017-315333)
- Elwood, P. et al. 2018. Healthy living and cancer: evidence from UK Biobank. ecancermedicalscience 12, article number: 792. (10.3332/ecancer.2018.792)
2017
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Wasan, H. S. et al. 2017. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology 18(9), pp. 1159-1171. (10.1016/S1470-2045(17)30457-6)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Battersby, N. J. et al. 2017. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials 18, article number: 394. (10.1186/s13063-017-2085-2)
- Geh, I. et al. 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management ofcancer of the Colon, rectum and anus (2017) - anal cancer. Colorectal Disease 19(S1), pp. 82-97. (10.1111/codi.13709)
- Gollins, S. et al. 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017) - multidisciplinary management. Colorectal Disease 19(S1), pp. 37-66. (10.1111/codi.13705)
- Lal, N. et al. 2017. Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. The Journal of Pathology: Clinical Research 3(3), pp. 155-170. (10.1002/cjp2.70)
- Hendry, M. et al. 2017. Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open 7(6), article number: e015413. (10.1136/bmjopen-2016-015413)
- Renfro, L. A. et al. 2017. Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the Aide et Recherche en Cancérologie digestive database. Journal of Clinical Oncology 35(17), pp. 1929-1937. (10.1200/JCO.2016.71.5771)
- Glynne-Jones, R., Adams, R., Lopes, A. and Meadows, H. 2017. Clinical endpoints in trials of chemoradiation for patients with anal cancer. Lancet Oncology 18(4), pp. e218-e227. (10.1016/S1470-2045(17)30190-0)
- Madi, A. et al. 2017. Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. Journal of Medical Genetics 54(8), pp. 567-571. (10.1136/jmedgenet-2016-104317)
- Seligmann, J. et al. 2017. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology 28(3), pp. 562-568. (10.1093/annonc/mdw645)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
- Adams, R. 2017. Surveillance of anal canal cancers. Surgical Oncology Clinics of North America 26(1), pp. 127-132. (10.1016/j.soc.2016.07.007)
- Wood, G. et al. 2017. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status. Anti-Cancer Drugs 28(5), pp. 546-550. (10.1097/CAD.0000000000000488)
2016
- Franko, J. et al. 2016. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology 17(12), pp. 1709-1719. (10.1016/S1470-2045(16)30500-9)
- Taylor, S. et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28(10), pp. e139-e147. (10.1016/j.clon.2016.06.004)
- Muirhead, R. et al. 2016. Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology 29(3), pp. 188-197. (10.1016/j.clon.2016.10.005)
- Gilbert, D. et al. 2016. Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: from consensus guidance to large-scale prospective audit, prior to future clinical trials. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, USA, 25-28 September 2016, Vol. 96. Vol. 2. Elsevier pp. S105-S106., (10.1016/j.ijrobp.2016.06.260)
- Sebag-Montefiore, D. et al. 2016. The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, USA, 25-28 September 2016, Vol. 96. Vol. 2. Elsevier pp. E164-E165., (10.1016/j.ijrobp.2016.06.1006)
- Weber, A. M., Drobnitzky, N., Devery, A. M., Bokobza, S. M., Adams, R., Maughan, T. S. and Ryan, A. J. 2016. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. Oncotarget 7(38), pp. 60807-60822. (10.18632/oncotarget.11845)
- Sharma, R. A. et al. 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13, pp. 627-642. (10.1038/nrclinonc.2016.79)
- Hendry, M. et al. 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open 6(4), article number: e011205. (10.1136/bmjopen-2016-011205)
- Ciardiello, F. et al. 2016. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. The Oncologist 21(3), pp. 292-300. (10.1634/theoncologist.2015-0279)
- Morris, E. J. A. et al. 2016. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clinical Oncology 28(8), pp. 522-531. (10.1016/j.clon.2016.02.002)
- Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T. and Bridgewater, J. 2016. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. British Journal of Cancer 114(6), pp. 612-615. (10.1038/bjc.2016.23)
- Renfro, L. A. et al. 2016. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. Journal of Clinical Oncology 34(2), pp. 144-150. (10.1200/JCO.2015.61.6441)
- Hubbard, G., Adams, R., Campbell, A., Kidd, L., Leslie, S. J., Munro, J. and Watson, A. 2016. Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study. BMJ Open 6(1), article number: e009284. (10.1136/bmjopen-2015-009284)
2015
- Richman, S. D. et al. 2015. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology 69(1), pp. 35-41. (10.1136/jclinpath-2015-203097)
- Hutchinson, R. A., Adams, R. A., McArt, D. G., Salto-Tellez, M., Jasani, B. and Hamilton, P. W. 2015. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine 13, article number: 217. (10.1186/s12967-015-0531-z)
- Shi, Q. et al. 2015. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology 33(1), pp. 22-28. (10.1200/JCO.2014.56.5887)
2014
- Baillie, J., Fitzgibbon, J., Simon, N., Adams, R. and Nelson, A. 2014. Developing meaningful public involvement in a cancer clinical trials unit. Presented at: COMET IV Meeting: Core Outcome Measures in Effectiveness Trials, Rome, Italy, 20-21 November 2014.
- Muirhead, R., Adams, R. A., Gilbert, D. C., Glynne-Jones, R., Harrison, M., Sebag-Montefiore, D. and Hawkins, M. A. 2014. Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26(11), pp. 720-721. (10.1016/j.clon.2014.08.001)
- Barbieri, M. et al. 2014. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Applied Health Economics and Health Policy 12(5), pp. 497-510. (10.1007/s40258-014-0115-8)
- Muirhead, R., Adams, R. A., Gilbert, D. C., Glynne-Jones, R., Harrison, M., Sebag-Montefiore, D. and Hawkins, M. A. 2014. Anal cancer: Developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26(11), pp. 720-721. (10.1016/j.clon.2014.08.001)
- Wasan, H. et al. 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. The Lancet Oncology 15(6), pp. 631-639. (10.1016/S1470-2045(14)70106-8)
- Glynne-Jones, R., Adams, R. A., Jitlal, M. and Meadows, H. 2014. End points in anal cancer: hopes for a common language. Journal of Clinical Oncology 32(12), pp. 1281-1282. (10.1200/JCO.2014.55.1515)
- Glynne-Jones, R., Adams, R. A., Jitlal, M. and Meadows, H. 2014. End points in anal cancer: Hopes for a common language. Journal of Clinical Oncology 32(12), pp. 1281-1282. (10.1200/JCO.2014.55.1515)
- Maughan, T. et al. 2014. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): A model for randomised controlled trials in the era of personalised medicine?. British Journal of Cancer 110, pp. 2178-2186. (10.1038/bjc.2014.182)
- Munro, J. et al. 2014. CRIB-the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4(2), article number: e004684. (10.1136/bmjopen-2013-004684)
- Munro, J. et al. 2014. CRIB - the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4(2), article number: e004684. (10.1136/bmjopen-2013-004684)
- Adams, R. and Maughan, T. 2014. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Review of Anticancer Therapy 7(4), pp. 503-518. (10.1586/14737140.7.4.503)
2013
- Smith, C. et al. 2013. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clinical Cancer Research 19(15), pp. 4104-4113. (10.1158/1078-0432.CCR-12-2581)
- Smith, C. et al. 2013. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Human Mutation 34(7), pp. 1026-1034. (10.1002/humu.22333)
- Glynne-Jones, R., Sebag-Montefiore, D., Adams, R., Gollins, S., Harrison, M., Meadows, H. M. and Jitlal, M. 2013. Prognostic factors for recurrence and survival in anal cancer. Cancer 119(4), pp. 748-755. (10.1002/cncr.27825)
- Türbachova, I. et al. 2013. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics 8(11), pp. 1226-1235. (10.4161/epi.26334)
2012
- Vale, C. L. et al. 2012. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treatment Reviews 38(6), pp. 618-625. (10.1016/j.ctrv.2011.11.002)
- Madi, A. et al. 2012. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer 107(7), pp. 1037-1043. (10.1038/bjc.2012.384)
- Dunlop, M. G. et al. 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk [Letter]. Nature Genetics 44(7), pp. 770-776. (10.1038/ng.2293)
- Gwynne, S. H., Webster, R., Adams, R. A., Mukherjee, S., Coles, B. and Staffurth, J. N. 2012. Image-guided radiotherapy for rectal cancer - A systematic review. Clinical Oncology 24(4), pp. 250-260. (10.1016/j.clon.2011.07.012)
- Gwynne, S., Mukherjee, S., Webster, R., Spezi, E., Staffurth, J., Coles, B. and Adams, R. 2012. Imaging for target volume delineation in rectal cancer radiotherapy - A systematic review. Clinical Oncology 24(1), pp. 52-63. (10.1016/j.clon.2011.10.001)
2011
- Glynne-Jones, R. et al. 2011. "Mind the gap" - The impact of variations in the duration of the treatment gap and overall treatment time in the first UK anal cancer trial (ACT I). International Journal of Radiation Oncology*Biology*Physics 81(5), pp. 1488-1494. (10.1016/j.ijrobp.2010.07.1995)
- Maughan, T. S. et al. 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 377(9783), pp. 2103-2114. (10.1016/S0140-6736(11)60613-2)
- Adams, R. A. et al. 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet Oncology 12(7), pp. 642-653. (10.1016/S1470-2045(11)70102-4)
- Shaw, P. and Adams, R. A. 2011. Where now for anti-EGF receptor therapies in colorectal cancer?. Expert Review of Anticancer Therapy 11(10), pp. 1543-1553. (10.1586/era.11.143)
2010
- Maughan, T., Adams, R., Wilson, R., Seymour, M., Meade, A. and Kaplan, R. 2010. Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option [Letter]. Journal of Clinical Oncology 28(17), pp. e275-e276. (10.1200/JCO.2009.27.8218)
2009
- Adams, R., Maughan, T. and Crosby, T. 2009. Colon and rectum. In: Hanna, L., Crosby, T. and Macbeth, F. eds. Practical Clinical Oncology. Cambridge University Press, pp. 159-173., (10.1017/CBO9780511545375.014)
- Adams, R. A. et al. 2009. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. British Journal of Cancer 100(2), pp. 251-258. (10.1038/sj.bjc.6604877)
- Wadhawan, A., Stephens, R. and Adams, R. 2009. Intermittent therapy in the palliative treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 9(1), pp. 125-134. (10.1586/14737140.9.1.125)
- Morgan, M. A. et al. 2009. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. British Journal of Surgery 96(11), pp. 1300-1307. (10.1002/bjs.6705)
- Clements, D., Dhruva Rao, P., Ramanathan, D., Adams, R., Maughan, T. S. and Davies, M. M. 2009. Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Disease 11(8), pp. 845-848. (10.1111/j.1463-1318.2008.01695.x)
2008
- Adams, R., Meade, A., Wasan, H., Griffiths, G. O. and Maughan, T. S. 2008. Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Review of Anticancer Therapy 8(8), pp. 1237-1245. (10.1586/14737140.8.8.1237)
2007
- Adams, R. et al. 2007. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. EJSO - European Journal of Surgical Oncology 33(3), pp. 307-313. (10.1016/j.ejso.2006.10.026)
- Shaw, P. H. S., Adams, R., Jordan, C. and Crosby, T. D. L. 2007. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clinical Oncology 19(1), pp. 87-95. (10.1016/j.clon.2006.09.009)
1993
- Hardie, K. R., Adams, R. A. and Towner, K. J. 1993. Transferrin-binding ability of invasive and commensal isolates of Haemophilus spp.. Journal of Medical Microbiology 39(3), pp. 218-224. (10.1099/00222615-39-3-218)
Articles
- Adams, R., Drinkwater, K., Gilbert, D. C., Hawkins, M. A., Montefiore, D. S., Thorpe, N. and Muirhead, R. 2024. The impact of national radiotherapy guidelines: the UK anal cancer story. Clinical Oncology 36, pp. 593-595. (10.1016/j.clon.2024.06.048)
- Cohen, R. et al. 2024. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. European Journal of Cancer 207, article number: 114160. (10.1016/j.ejca.2024.114160)
- Murphy, A. D. et al. 2024. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. International Journal of Gynecological Cancer 34, pp. 1034-1040. (10.1136/ijgc-2024-005455)
- Karapetis, C. S. et al. 2024. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. British Journal of Cancer 130, pp. 1269–1278. (10.1038/s41416-024-02604-y)
- Cohen, R. et al. 2024. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. European Journal of Cancer 199, article number: 113537. (10.1016/j.ejca.2024.113537)
- Coyle, V. et al. 2024. Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial. Clinical Microbiology and Infection 30(1), pp. 92-99. (10.1016/j.cmi.2023.07.021)
- Elwood, P. et al. 2024. Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against. British Journal of Cancer 130, pp. 3-8. (10.1038/s41416-023-02506-5)
- Retzer, A. et al. 2023. Development of a core outcome set for use in adult primary glioma phase III interventional trials: A mixed methods study. Neuro-Oncology Advances 5(1), article number: vdad096. (10.1093/noajnl/vdad096)
- Richman, S. D. et al. 2023. FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology 76(8), pp. 548-554. (10.1136/jclinpath-2022-208233)
- Ou, F. et al. 2023. Evaluation of intratumoral response heterogeneity in metastatic colorectal cancer and Its impact on patient overall survival: findings from 10,551 patients in the ARCAD database. Cancers 15(16), article number: 4117. (10.3390/cancers15164117)
- Mukherjee, S. et al. 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61, article number: 102059. (10.1016/j.eclinm.2023.102059)
- Spary, L. K. et al. 2023. Clinical analysis of the colorectal cohort within the Wales cancer biobank: a study of outcomes and genetic screening. Journal of Cancer Therapy 14(7), pp. 317-344. (10.4236/jct.2023.147027)
- Margalit, O. et al. 2023. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.. European Journal of Cancer 178, pp. 162-170. (10.1016/j.ejca.2022.10.022)
- Brown, L. C. et al. 2022. Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. Efficacy and Mechanism Evaluation 9, article number: 9. (10.3310/HTNB6908)
- Franko, J. et al. 2022. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. European Journal of Cancer 174, pp. 142-152. (10.1016/j.ejca.2022.07.021)
- Retzer, A. et al. 2022. Development of a core outcome set and identification of patient-reportable outcomes for primary brain tumour trials: protocol for the COBra study. BMJ Open 12, article number: 57712. (10.1136/bmjopen-2021-057712)
- Henderson, R. H. et al. 2022. Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. Journal of Cancer Policy 33, article number: 100342. (10.1016/j.jcpo.2022.100342)
- Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
- Brown, S. R. et al. 2022. A road map for designing phase I clinical trials of radiotherapy-novel agent combinations. Clinical Cancer Research 28(17), pp. 3639-3651. (10.1158/1078-0432.CCR-21-4087)
- Margalit, O. et al. 2022. P-106 Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. Annals of Oncology 33(S4), pp. S287-S287. (10.1016/j.annonc.2022.04.196)
- Speirs, V., Cox, A., Chelala, C., James, J. A., Adams, R. A. and Jones, J. L. 2022. A biobank perspective on use of tissue samples donated by trial participants. The Lancet Oncology 23(5), article number: e205. (10.1016/S1470-2045(22)00186-3)
- McCleary, N. J. et al. 2022. Metastatic colorectal cancer outcomes by age among ARCAD first- and second-line Clinical trials. JNCI Cancer Spectrum 6(2), article number: pkac014. (10.1093/jncics/pkac014)
- Adams, R., Wilson, R., Brown, L. and Maughan, T. 2022. Reply to A. Kurreck et al and M.S. Copur et al. Journal of Clinical Oncology 40(11), pp. 1263-1264. (10.1200/JCO.21.02806)
- Brown, L. C. et al. 2022. Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials 19(2), pp. 146-157. (10.1177/17407745211069879)
- Papamichael, D. et al. 2022. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. European Journal of Cancer 163, pp. 1-15. (10.1016/j.ejca.2021.12.007)
- Goldberg, R. M. et al. 2022. Clinical trial endpoints in metastatic cancer: using individual participant data to inform future trials methodology. Journal of the National Cancer Institute 114(6), pp. 819-828. (10.1093/jnci/djab218)
- Yin, J. et al. 2021. Prognostic and predictive impact of primary tumor sidedness for previously untreated advanced colorectal cancer. Journal of the National Cancer Institute 113(12), pp. 1705-1713., article number: djab112. (10.1093/jnci/djab112)
- Clifford, R. E., Harji, D., Poynter, L., Jackson, R., Adams, R., Fearnhead, N. S. and Vimalachandran, D. 2021. Rectal cancer management during the COVID-19 pandemic (ReCaP): multicentre prospective observational study. British Journal of Surgery 108(11), pp. 1270-1273., article number: znab129. (10.1093/bjs/znab129)
- Adams, R. A. et al. 2021. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology 39(33), pp. 3693-3704. (10.1200/JCO.21.01436)
- Seligmann, J. F. et al. 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology 39(33), pp. 3705-3715. (10.1200/JCO.21.01435)
- Cohen, R. et al. 2021. BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. JNCI: Journal of the National Cancer Institute 113(10), pp. 1386–1395-1395. (10.1093/jnci/djab042)
- ten Hoorn, S. et al. 2021. Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer 125, pp. 1080-1088. (10.1038/s41416-021-01477-9)
- Adams, R. et al. 2021. Treatment breaks in first line treatment of advanced colorectal cancer: an individual patient data meta-analysis. Cancer Treatment Reviews 99, article number: 102226. (10.1016/j.ctrv.2021.102226)
- Henderson, R. H. et al. 2021. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. The Lancet Gastroenterology & Hepatology 6(9), pp. 709-722. (10.1016/S2468-1253(21)00147-3)
- Hanna, C. R. et al. 2021. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology 16(1), article number: 163. (10.1186/s13014-021-01888-1)
- Hanna, C. R., O'Cathail, S. M., Graham, J., Adams, R. and Roxburgh, C. S. 2021. Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology 4(2), pp. 86-104. (10.36401/JIPO-20-31)
- RECOVERY Collaborative Group, ., Adams, R. and Forton, J. 2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet 397(10289), pp. 2049-2059. (10.1016/s0140-6736(21)00897-7)
- Abani, O. et al. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397(10285), pp. 1637-1645. (10.1016/S0140-6736(21)00676-0)
- Hanna, C. et al. 2021. Intensity-modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology 33(4), pp. 214-223. (10.1016/j.clon.2020.12.011)
- Bach, S. P. et al. 2021. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterology and Hepatology 6(2), pp. 92-105. (10.1016/S2468-1253(20)30333-2)
- Horby, P. et al. 2021. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 384(8), pp. 693-704. (10.1056/NEJMoa2021436)
- Abaleke, E. et al. 2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397(10274), pp. 605-612. (10.1016/S0140-6736(21)00149-5)
- Yin, J. et al. 2021. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology 13, pp. 1-11. (10.1177/17588359211020547)
- Horby, P. et al. 2020. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine 383(21), pp. 2030-2040. (10.1056/NEJMoa2022926)
- Glynne-Jones, R., Meadows, H., Lopes, A., Muirhead, R., Sebag-Montefiore, D. and Adams, R. 2020. Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. Annals of Oncology 31(11), pp. 1587-1588. (10.1016/j.annonc.2020.08.2097)
- Glynne-Jones, R., Meadows, H. M., Lopes, A., Muirhead, R., Sebag-Montefiore, D. and Adams, R. 2020. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Annals of Oncology 31(10), pp. 1376-1385. (10.1016/j.annonc.2020.06.012)
- Germetaki, T. et al. 2020. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncology 16(28), pp. 2177-2189. (10.2217/fon-2020-0523)
- Barber, P. R. et al. 2020. HER2-HER3 heterodimer quantification by FRET-FILM and patient subclass analysis of the COIN colorectal trial. JNCI: Journal of the National Cancer Institute 112(9), pp. 944-954. (10.1093/jnci/djz231)
- Karapetis, C. S. et al. 2020. 434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database. Annals of Oncology 31(S4), article number: S426. (10.1016/j.annonc.2020.08.545)
- Papamichael, D. et al. 2020. 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database. Annals of Oncology 31, article number: S425. (10.1016/j.annonc.2020.08.543)
- Rao, S. et al. 2020. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil cersus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology 38(22), pp. 2510-2518. (10.1200/JCO.19.03266)
- O'Cathail, S. M. et al. 2020. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology 15, article number: 151. (10.1186/s13014-020-01593-5)
- Forde, C. et al. 2020. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials 21, article number: 431. (10.1186/s13063-020-04241-1)
- Gilbert, A. et al. 2020. UK national cohort of anal cancer treated with intensity-modulated radiotherapy: one-year oncological and patient-reported outcomes. European Journal of Cancer 128, pp. 7-16. (10.1016/j.ejca.2019.12.022)
- Chalmers, A. et al. 2020. CTRad 10 years on: from 10-point plan to top 10 achievements. Clinical Oncology 32(1), pp. 9-12. (10.1016/j.clon.2019.09.043)
- Joharatnam-Hogan, N. et al. 2019. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology 4(11), pp. 854-862. (10.1016/S2468-1253(19)30289-4)
- Gilbert, A. et al. 2019. 535P - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5). Annals of Oncology 30(S5), pp. v203-v204. (10.1093/annonc/mdz246.013)
- Vallance, A. et al. 2019. Making an IMPACT: A priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer. EJSO - European Journal of Surgical Oncology 45(9), pp. 1467-1574. (10.1016/j.ejso.2019.04.005)
- Renehan, A. et al. 2019. Early stage anal margin cancer: towards evidence‐based management. Colorectal Disease 21(4), pp. 387-391. (10.1111/codi.14571)
- Fish, R. et al. 2018. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterology and Hepatology 3(12), pp. 865-873. (10.1016/S2468-1253(18)30264-4)
- West, H. et al. 2018. Role for nucleotide excision repair gene variants in oxaliplatin-induced peripheral neuropathy. JCO Precision Oncology 2, pp. 1-18. (10.1200/PO.18.00090)
- Salem, M. E. et al. 2018. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. European Journal of Cancer 103, pp. 205-213. (10.1016/j.ejca.2018.08.020)
- Cross, W. et al. 2018. The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution 2(10), pp. 1661-1672. (10.1038/s41559-018-0642-z)
- Elwood, P. et al. 2018. Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. PLoS ONE 13(9), pp. e0203957. (10.1371/journal.pone.0203957)
- Madi, A. et al. 2018. Pharmacogenetic analyses of 2,183 patients with advanced colorectal cancer; Potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.. European Journal of Cancer 102, pp. 31-39. (10.1016/j.ejca.2018.07.009)
- Goey, K. K. et al. 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer 100, pp. 35-45. (10.1016/j.ejca.2018.05.010)
- Gollins, S. et al. 2018. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer (10.1038/s41416-018-0209-4)
- Jones, C. M. et al. 2018. Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort. International Journal of Radiation Oncology - Biology - Physics 101(5), pp. 1202-1211. (10.1016/j.ijrobp.2018.04.033)
- Sjoquist, K. M. et al. 2018. Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project. JNCI: Journal of the National Cancer Institute 110(6), pp. 638-648. (10.1093/jnci/djx253)
- Rose, G. et al. 2018. The cardiopulmonary exercise test grey zone; optimising fitness stratification by application of critical difference. British Journal of Anaesthesia 120(6), pp. 1187-1194. (10.1016/j.bja.2018.02.062)
- Alderdice, M. et al. 2018. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. The Journal of Pathology 245(1), pp. 19-28. (10.1002/path.5051)
- Adams, R. et al. 2018. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2?3 randomised trial. Lancet Gastroenterology and Hepatology 3(3), pp. 162-171. (10.1016/S2468-1253(17)30394-1)
- Lawler, M. et al. 2018. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut 67(1), pp. 179-193. (10.1136/gutjnl-2017-315333)
- Elwood, P. et al. 2018. Healthy living and cancer: evidence from UK Biobank. ecancermedicalscience 12, article number: 792. (10.3332/ecancer.2018.792)
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Wasan, H. S. et al. 2017. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology 18(9), pp. 1159-1171. (10.1016/S1470-2045(17)30457-6)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Battersby, N. J. et al. 2017. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials 18, article number: 394. (10.1186/s13063-017-2085-2)
- Geh, I. et al. 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management ofcancer of the Colon, rectum and anus (2017) - anal cancer. Colorectal Disease 19(S1), pp. 82-97. (10.1111/codi.13709)
- Gollins, S. et al. 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017) - multidisciplinary management. Colorectal Disease 19(S1), pp. 37-66. (10.1111/codi.13705)
- Lal, N. et al. 2017. Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. The Journal of Pathology: Clinical Research 3(3), pp. 155-170. (10.1002/cjp2.70)
- Hendry, M. et al. 2017. Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open 7(6), article number: e015413. (10.1136/bmjopen-2016-015413)
- Renfro, L. A. et al. 2017. Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the Aide et Recherche en Cancérologie digestive database. Journal of Clinical Oncology 35(17), pp. 1929-1937. (10.1200/JCO.2016.71.5771)
- Glynne-Jones, R., Adams, R., Lopes, A. and Meadows, H. 2017. Clinical endpoints in trials of chemoradiation for patients with anal cancer. Lancet Oncology 18(4), pp. e218-e227. (10.1016/S1470-2045(17)30190-0)
- Madi, A. et al. 2017. Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. Journal of Medical Genetics 54(8), pp. 567-571. (10.1136/jmedgenet-2016-104317)
- Seligmann, J. et al. 2017. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology 28(3), pp. 562-568. (10.1093/annonc/mdw645)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
- Adams, R. 2017. Surveillance of anal canal cancers. Surgical Oncology Clinics of North America 26(1), pp. 127-132. (10.1016/j.soc.2016.07.007)
- Wood, G. et al. 2017. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status. Anti-Cancer Drugs 28(5), pp. 546-550. (10.1097/CAD.0000000000000488)
- Franko, J. et al. 2016. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology 17(12), pp. 1709-1719. (10.1016/S1470-2045(16)30500-9)
- Taylor, S. et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28(10), pp. e139-e147. (10.1016/j.clon.2016.06.004)
- Muirhead, R. et al. 2016. Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology 29(3), pp. 188-197. (10.1016/j.clon.2016.10.005)
- Weber, A. M., Drobnitzky, N., Devery, A. M., Bokobza, S. M., Adams, R., Maughan, T. S. and Ryan, A. J. 2016. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. Oncotarget 7(38), pp. 60807-60822. (10.18632/oncotarget.11845)
- Sharma, R. A. et al. 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13, pp. 627-642. (10.1038/nrclinonc.2016.79)
- Hendry, M. et al. 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open 6(4), article number: e011205. (10.1136/bmjopen-2016-011205)
- Ciardiello, F. et al. 2016. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. The Oncologist 21(3), pp. 292-300. (10.1634/theoncologist.2015-0279)
- Morris, E. J. A. et al. 2016. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clinical Oncology 28(8), pp. 522-531. (10.1016/j.clon.2016.02.002)
- Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T. and Bridgewater, J. 2016. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. British Journal of Cancer 114(6), pp. 612-615. (10.1038/bjc.2016.23)
- Renfro, L. A. et al. 2016. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. Journal of Clinical Oncology 34(2), pp. 144-150. (10.1200/JCO.2015.61.6441)
- Hubbard, G., Adams, R., Campbell, A., Kidd, L., Leslie, S. J., Munro, J. and Watson, A. 2016. Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study. BMJ Open 6(1), article number: e009284. (10.1136/bmjopen-2015-009284)
- Richman, S. D. et al. 2015. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology 69(1), pp. 35-41. (10.1136/jclinpath-2015-203097)
- Hutchinson, R. A., Adams, R. A., McArt, D. G., Salto-Tellez, M., Jasani, B. and Hamilton, P. W. 2015. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine 13, article number: 217. (10.1186/s12967-015-0531-z)
- Shi, Q. et al. 2015. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology 33(1), pp. 22-28. (10.1200/JCO.2014.56.5887)
- Muirhead, R., Adams, R. A., Gilbert, D. C., Glynne-Jones, R., Harrison, M., Sebag-Montefiore, D. and Hawkins, M. A. 2014. Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26(11), pp. 720-721. (10.1016/j.clon.2014.08.001)
- Barbieri, M. et al. 2014. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Applied Health Economics and Health Policy 12(5), pp. 497-510. (10.1007/s40258-014-0115-8)
- Muirhead, R., Adams, R. A., Gilbert, D. C., Glynne-Jones, R., Harrison, M., Sebag-Montefiore, D. and Hawkins, M. A. 2014. Anal cancer: Developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26(11), pp. 720-721. (10.1016/j.clon.2014.08.001)
- Wasan, H. et al. 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. The Lancet Oncology 15(6), pp. 631-639. (10.1016/S1470-2045(14)70106-8)
- Glynne-Jones, R., Adams, R. A., Jitlal, M. and Meadows, H. 2014. End points in anal cancer: hopes for a common language. Journal of Clinical Oncology 32(12), pp. 1281-1282. (10.1200/JCO.2014.55.1515)
- Glynne-Jones, R., Adams, R. A., Jitlal, M. and Meadows, H. 2014. End points in anal cancer: Hopes for a common language. Journal of Clinical Oncology 32(12), pp. 1281-1282. (10.1200/JCO.2014.55.1515)
- Maughan, T. et al. 2014. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): A model for randomised controlled trials in the era of personalised medicine?. British Journal of Cancer 110, pp. 2178-2186. (10.1038/bjc.2014.182)
- Munro, J. et al. 2014. CRIB-the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4(2), article number: e004684. (10.1136/bmjopen-2013-004684)
- Munro, J. et al. 2014. CRIB - the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4(2), article number: e004684. (10.1136/bmjopen-2013-004684)
- Adams, R. and Maughan, T. 2014. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Review of Anticancer Therapy 7(4), pp. 503-518. (10.1586/14737140.7.4.503)
- Smith, C. et al. 2013. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clinical Cancer Research 19(15), pp. 4104-4113. (10.1158/1078-0432.CCR-12-2581)
- Smith, C. et al. 2013. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Human Mutation 34(7), pp. 1026-1034. (10.1002/humu.22333)
- Glynne-Jones, R., Sebag-Montefiore, D., Adams, R., Gollins, S., Harrison, M., Meadows, H. M. and Jitlal, M. 2013. Prognostic factors for recurrence and survival in anal cancer. Cancer 119(4), pp. 748-755. (10.1002/cncr.27825)
- Türbachova, I. et al. 2013. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics 8(11), pp. 1226-1235. (10.4161/epi.26334)
- Vale, C. L. et al. 2012. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treatment Reviews 38(6), pp. 618-625. (10.1016/j.ctrv.2011.11.002)
- Madi, A. et al. 2012. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer 107(7), pp. 1037-1043. (10.1038/bjc.2012.384)
- Dunlop, M. G. et al. 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk [Letter]. Nature Genetics 44(7), pp. 770-776. (10.1038/ng.2293)
- Gwynne, S. H., Webster, R., Adams, R. A., Mukherjee, S., Coles, B. and Staffurth, J. N. 2012. Image-guided radiotherapy for rectal cancer - A systematic review. Clinical Oncology 24(4), pp. 250-260. (10.1016/j.clon.2011.07.012)
- Gwynne, S., Mukherjee, S., Webster, R., Spezi, E., Staffurth, J., Coles, B. and Adams, R. 2012. Imaging for target volume delineation in rectal cancer radiotherapy - A systematic review. Clinical Oncology 24(1), pp. 52-63. (10.1016/j.clon.2011.10.001)
- Glynne-Jones, R. et al. 2011. "Mind the gap" - The impact of variations in the duration of the treatment gap and overall treatment time in the first UK anal cancer trial (ACT I). International Journal of Radiation Oncology*Biology*Physics 81(5), pp. 1488-1494. (10.1016/j.ijrobp.2010.07.1995)
- Maughan, T. S. et al. 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 377(9783), pp. 2103-2114. (10.1016/S0140-6736(11)60613-2)
- Adams, R. A. et al. 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet Oncology 12(7), pp. 642-653. (10.1016/S1470-2045(11)70102-4)
- Shaw, P. and Adams, R. A. 2011. Where now for anti-EGF receptor therapies in colorectal cancer?. Expert Review of Anticancer Therapy 11(10), pp. 1543-1553. (10.1586/era.11.143)
- Maughan, T., Adams, R., Wilson, R., Seymour, M., Meade, A. and Kaplan, R. 2010. Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option [Letter]. Journal of Clinical Oncology 28(17), pp. e275-e276. (10.1200/JCO.2009.27.8218)
- Adams, R. A. et al. 2009. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. British Journal of Cancer 100(2), pp. 251-258. (10.1038/sj.bjc.6604877)
- Wadhawan, A., Stephens, R. and Adams, R. 2009. Intermittent therapy in the palliative treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 9(1), pp. 125-134. (10.1586/14737140.9.1.125)
- Morgan, M. A. et al. 2009. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. British Journal of Surgery 96(11), pp. 1300-1307. (10.1002/bjs.6705)
- Clements, D., Dhruva Rao, P., Ramanathan, D., Adams, R., Maughan, T. S. and Davies, M. M. 2009. Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Disease 11(8), pp. 845-848. (10.1111/j.1463-1318.2008.01695.x)
- Adams, R., Meade, A., Wasan, H., Griffiths, G. O. and Maughan, T. S. 2008. Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Review of Anticancer Therapy 8(8), pp. 1237-1245. (10.1586/14737140.8.8.1237)
- Adams, R. et al. 2007. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. EJSO - European Journal of Surgical Oncology 33(3), pp. 307-313. (10.1016/j.ejso.2006.10.026)
- Shaw, P. H. S., Adams, R., Jordan, C. and Crosby, T. D. L. 2007. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clinical Oncology 19(1), pp. 87-95. (10.1016/j.clon.2006.09.009)
- Hardie, K. R., Adams, R. A. and Towner, K. J. 1993. Transferrin-binding ability of invasive and commensal isolates of Haemophilus spp.. Journal of Medical Microbiology 39(3), pp. 218-224. (10.1099/00222615-39-3-218)
Book sections
- Adams, R., Maughan, T. and Crosby, T. 2009. Colon and rectum. In: Hanna, L., Crosby, T. and Macbeth, F. eds. Practical Clinical Oncology. Cambridge University Press, pp. 159-173., (10.1017/CBO9780511545375.014)
Conferences
- Ajakaiye, A. et al. 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting, Dublin, Ireland, 16-18 October 2024, Vol. 34. BMJ Publishing Group pp. A350-A351., (10.1136/ijgc-2024-IGCS.611)
- Jones, S. E. F. et al. 2023. Launching the PICCOS trial: PIPAC in cancers of the colon, ovary and stomach. Presented at: European Society of Gynaecological Society Congress, Istanbul, Turkey, 28 September - 01 October 2023. BMJ Publishing Group, (10.1136/ijgc-2023-ESGO.690)
- Retzer, A. et al. 2022. Core outcomes in brain tumour trials – the COBra study review of glioma trial registration data. Presented at: BNOS 2022, Liverpool, 22-24 June 2022, Vol. 24. Oxford University Press, (10.1093/neuonc/noac200.019)
- Baddeley, E. et al. 2022. Evaluation of patient and public involvement in the development of a patient reported outcome set in brain tumour trials (COBra Study). Presented at: National PROMs Annual Research Conference, National, 14-15 June 2022.
- Jayson, G. et al. 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference, 2021.
- Madi, A. et al. 2018. Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII22., (10.1093/annonc/mdy269.072)
- Rao, S. et al. 2018. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII715-VIII716., (10.1093/annonc/mdy424.022)
- Bhoday, J., Glimelius, B., Tait, D., Glynne-Jones, R., Adams, R. and Brown, G. 2018. Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. Presented at: Future Horizons International Experts Meeting in Colorectal Cancer 2015, London, England, 25 June 2015 Presented at Wale, A. and Brown, G. eds., Vol. 20. Vol. S`. Wiley pp. 97-99., (10.1111/codi.14088)
- Gilbert, D. et al. 2016. Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: from consensus guidance to large-scale prospective audit, prior to future clinical trials. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, USA, 25-28 September 2016, Vol. 96. Vol. 2. Elsevier pp. S105-S106., (10.1016/j.ijrobp.2016.06.260)
- Sebag-Montefiore, D. et al. 2016. The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, USA, 25-28 September 2016, Vol. 96. Vol. 2. Elsevier pp. E164-E165., (10.1016/j.ijrobp.2016.06.1006)
- Baillie, J., Fitzgibbon, J., Simon, N., Adams, R. and Nelson, A. 2014. Developing meaningful public involvement in a cancer clinical trials unit. Presented at: COMET IV Meeting: Core Outcome Measures in Effectiveness Trials, Rome, Italy, 20-21 November 2014.
Ymchwil
Datblygu a chyflwyno treialon clinigol canser, gyda'r bwriad o ddefnyddio'r wyddoniaeth orau trwy waith tîm cydweithredol i ateb cwestiynau a newid ymarfer sy'n berthnasol i gleifion, diagnosis o ganser
Addysgu
Rwyf wedi bod yn addysgwr tymor hir ar lefelau israddedig, ôl-raddedig a chydweithwyr.
Gellid dadlau fy mod yn traddodi darlithoedd mewn cyfarfodydd cenedlaethol a rhyngwladol
Bywgraffiad
Mae Richard Adams yn Athro ac Oncolegydd Clinigol Ymgynghorol Anrhydeddus ym Mhrifysgol Caerdydd a Chanolfan Ganser Felindre. Mae'n Gyfarwyddwr Treialon Canser ar gyfer y Ganolfan Ymchwil Treialon a Chyfarwyddwr clinigol Banc Canser Cymru. Mae ei ymarfer clinigol a'i ymchwil yn canolbwyntio ar ganserau gastroberfeddol is. Mae'n gadeirydd is-grŵp CTRad WS2 (ymchwil radiotherapi yn y DU) Sefydliad Ymchwil Canser Cenedlaethol a Phanel Adolygu Arbenigol Clinigol CRUK. Mae'n weithgar mewn sefydliadau ymchwil cenedlaethol a rhyngwladol gan gynnwys IRCI y Fenter Canser Prin Ryngwladol (ar gyfer canser rhefrol) ac ARCAD (ar gyfer canser y colorectal metastatig).
Mae Richard yn cadeirio'r grŵp datblygu biomarciwr ar gyfer treial cam III III FOCUS4 y DU mewn canser colorectal metastatig ac mae'n Brif ymchwilydd ar gyfer treialon FOCUS4D ac N. Mae'n arwain ar y rhaglen sicrhau ansawdd radiotherapi ar gyfer treialon canser rectal y DU. Mae ganddo rôl yng Nghymru i ennyn diddordeb ymchwilwyr mewn ymchwil glinigol canser. Mae'n goruchwylio ymchwil drosiadol gydweithredol mewn nifer o dreialon canser colorectal cam II / III. Roedd yn aelod sefydlol o gyswllt Gofal Canser Sierra Leone De Cymru ac mae bellach yn gadeirydd.
Aelodaethau proffesiynol
- Chair Ano-rectal subgroup of the National Cancer Research Institute clinical study group (CSG) 2012 – onwards
- International Executive board member ARCAD Advanced Colorectal cancer database international research group and UK member 2011-present
- International Rare Cancer Initiative Anal Cancer Group member 2011-present
- Lead for radiotherapy Quality Assurance for ARISTOTLE/COPERNICUS and TREC trials 2011-present
- NCRI Colorectal cancer Clinical Studies Group (CSG) member 2010-present
- National Cancer Research Institute CTRad CSG phase I/II subgroup chair 2014-presetn
- ESMO scientific committee lower gastrointestinal cancers 2014- present
- ASCO - member
Safleoedd academaidd blaenorol
2017-present: Professor in Cancer Clinical trials Cardiff University
2013-2017: Reader in Clinical Oncology Cardiff University
2007-2013: Senior Lecturer in Clinical Oncology Cardiff University
2007-present: Honorary Consultant in Clinical Oncology Velindre NHS Trust
2007-present: Honorary Consultant in Clinical Oncology Cardiff and Vale University Health Board
Contact Details
AdamsRA3@caerdydd.ac.uk
+44 29206 87456
Neuadd Meirionnydd, Ystafell 6ed Llawr, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
+44 29206 87456
Neuadd Meirionnydd, Ystafell 6ed Llawr, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
